Latest news


PCI Biotech: US patent for the vaccine technology (fimaVACC) with a new important class of adjuvants

Posted on Mar 26, 2020

Oslo (Norway), 26 March 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has informed the company that a new US patent will be granted early April 2020. The US patent covers the use of fimaVacc in combination with a new important class […]

PCI Biotech: Update on operational implications of the corona pandemic

Posted on Mar 25, 2020

Oslo, Norway, 25 March, 2020: PCI Biotech (OSE: PCIB) has closely monitored potential implications on its short- and long-term operations following the latest development of the coronavirus pandemic. PCI Biotech’s over-riding priority is the safety of its staff, patients participating in the clinical trial and its collaborators. The main identified near-term implications concern the RELEASE […]

Fourth quarter and preliminary 2019 results

Posted on Feb 26, 2020

Oslo (Norway), 26 February 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim fourth quarter and preliminary 2019 results. Please find enclosed the report and presentation. 2019 in review – focus on execution of the pivotal RELEASE study          The overall survival data for Phase I patients receiving the pivotal […]